Clinical Trial Update: VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating VEGFR/PDGFR dual kinase inhibitor X-82 in combination with Everolimus for pancreatic neuroendocrine tumor; the study is te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Pancreatic Neoplasms
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Everolimus (everolimus)
• X-82

Snippet

Sponsor: Washington University School of Medicine | Conditions: Adenocarcinoma, Pancreatic Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-06-10